Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: questions, myths and facts.

Savica V, Bellinghieri G, Monardo P, Muraca U, Santoro D.

J Nephrol. 2013 May-Jun;26(3):456-64. doi: 10.5301/jn.5000189. Epub 2012 Jul 4. Review.

PMID:
22782328
2.

Urine therapy through the centuries.

Savica V, Calò LA, Santoro D, Monardo P, Mallamace A, Bellinghieri G.

J Nephrol. 2011 May-Jun;24 Suppl 17:S123-5. doi: 10.5301/JN.2011.6463.

PMID:
21614793
3.

Salivary glands: a new player in phosphorus metabolism.

Savica V, Calò LA, Santoro D, Monardo P, Santoro G, Muraca U, Davis PA, Bellinghieri G.

J Ren Nutr. 2011 Jan;21(1):39-42. doi: 10.1053/j.jrn.2010.11.007. Review.

PMID:
21195917
4.

Phosphorus: the philosopher's stone discovered in 1669.

Savica V, Santoro D, Mallamace A, Monardo P, Davis PA, Calò LA, Li Vecchi M, Muraca U, Bellinghieri G.

J Nephrol. 2009 Nov-Dec;22 Suppl 14:60-3.

PMID:
20013733
5.

[Management of hyperphosphatemia in patients with chronic kidney disease].

Savica V, Santoro D, Monardo P, Mallamace A, Bellinghieri G.

G Ital Nefrol. 2009 Jul-Aug;26 Suppl 46:58-61. Italian.

PMID:
19644820
6.

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis.

Savica V, Santoro D, Monardo P, Mallamace A, Bellinghieri G.

Ther Clin Risk Manag. 2008 Aug;4(4):821-6.

7.

Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.

Savica V, Calò LA, Monardo P, Santoro D, Mallamace A, Muraca U, Bellinghieri G.

J Ren Nutr. 2009 Jan;19(1):69-72. doi: 10.1053/j.jrn.2008.10.024.

PMID:
19121775
8.

Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G.

J Am Soc Nephrol. 2009 Mar;20(3):639-44. doi: 10.1681/ASN.2008020130. Epub 2008 Nov 19.

9.

High phosphate content beverages in dialysis patients: relevance for hyperphosphatemia and cardiovascular risk.

Savica V, Calò LA, Monardo P, Caldarera R, Cavaleri A, Santoro D, Muraca U, Mallamace A, Bellinghieri G.

Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):e39-40. doi: 10.1016/j.numecd.2008.03.003. Epub 2008 Jun 20. No abstract available.

PMID:
18571909
10.

Time-dependent effect of sevelamerHCl on the cardiovascular system.

Savica V, Monardo P, Santoro D, Mallamace A, Bellinghieri G.

Nephrol Dial Transplant. 2008 Jun;23(6):2102-3; author reply 2103. doi: 10.1093/ndt/gfn104. Epub 2008 Mar 19. No abstract available.

PMID:
18353887
11.

Salivary phosphate secretion in chronic kidney disease.

Savica V, Calò L, Santoro D, Monardo P, Granata A, Bellinghieri G.

J Ren Nutr. 2008 Jan;18(1):87-90.

PMID:
18089451
12.
13.

A new approach to the evaluation of hyperphosphatemia in chronic kidney disease.

Savica V, Calò LA, Granata A, Caldarera R, Cavaleri A, Santoro D, Monardo P, Savica R, Muraca U, Bellinghieri G.

Clin Nephrol. 2007 Oct;68(4):216-21.

PMID:
17969488
14.

Nutritional status in hemodialysis patients: options for on-line convective treatment.

Savica V, Ciolino F, Monardo P, Mallamace A, Savica R, Santoro D, Bellinghieri G.

J Ren Nutr. 2006 Jul;16(3):237-40.

PMID:
16825027
15.

Phosphate binders and management of hyperphosphataemia in end-stage renal disease.

Savica V, Calò LA, Monardo P, Santoro D, Bellinghieri G.

Nephrol Dial Transplant. 2006 Aug;21(8):2065-8. Epub 2006 Jun 9. Review. No abstract available.

PMID:
16766546
16.

Newer aspects of carnitine metabolism in uremia.

Savica V, Calvani M, Benatti P, Santoro D, Monardo P, Mallamace A, Savica R, Bellinghieri G.

Semin Nephrol. 2006 Jan;26(1):52-5. Review.

PMID:
16412827
17.

L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients.

Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M, Bellinghieri G, Kopple JD.

J Ren Nutr. 2005 Apr;15(2):225-30.

PMID:
15827896
18.

Carnitine system in uremic patients: molecular and clinical aspects.

Savica V, Calvani M, Benatti P, Santoro D, Monardo P, Peluso G, Bellinghieri G.

Semin Nephrol. 2004 Sep;24(5):464-8. Review.

PMID:
15490412
19.

[The status of peritoneal dialysis in Piedmont by 12/31/1997].

Giachino G, Saltarelli M, Chiappero F, Monardo P, Hamido M, Alfieri V, Iadarola AM, Anania P, Salomone M.

Minerva Urol Nefrol. 2001 Jun;53(2):75-9. Italian.

PMID:
11455315
20.

A sampling of the yeast proteome.

Futcher B, Latter GI, Monardo P, McLaughlin CS, Garrels JI.

Mol Cell Biol. 1999 Nov;19(11):7357-68.

21.

A Saccharomyces cerevisiae Internet protein resource now available.

Latter GI, Boutell T, Monardo PJ, Kobayashi R, Futcher B, Mclaughlin CS, Garrels JI.

Electrophoresis. 1995 Jul;16(7):1170-4.

PMID:
7498160
22.
23.

REF52 on Global Gel Navigator: an internet-accessible two-dimensional gel electrophoresis database.

Boutell T, Garrels JI, Franza BR, Monardo PJ, Latter GI.

Electrophoresis. 1994 Nov;15(11):1487-90.

PMID:
7895734
24.

A distributed system for two-dimensional gel analysis.

Monardo PJ, Boutell T, Garrels JI, Latter GI.

Comput Appl Biosci. 1994 Apr;10(2):137-43.

PMID:
8019861
25.

Renal function evaluation in an adult female with cat-eye syndrome.

Bellinghieri G, Triolo O, Stella NC, Gemelli M, Musolino R, Monardo P, Savica V.

Am J Nephrol. 1994;14(1):76-9.

PMID:
8017487
26.

Endocrine-metabolic hypertension.

DeSanto NG, Anastasio P, Spitali L, Monardo P, Pollastro RM, Papalia T, Massimo L, De Mercato R, Di Leo VA, et al.

Child Nephrol Urol. 1992;12(2-3):147-53. Review. No abstract available. Erratum in: Child Nephrol Urol 1992;12(4):207. De Mercoto R [corrected to De Mercato R].

PMID:
1320999

Supplemental Content

Loading ...
Support Center